These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16313067)

  • 1. Perspectives of contraceptive choices for men.
    Lohiya NK; Manivannan B; Bhande SS; Panneerdoss S; Garg S
    Indian J Exp Biol; 2005 Nov; 43(11):1042-7. PubMed ID: 16313067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proton NMR study of the effect of a new intravasal injectable male contraceptive RISUG on seminal plasma metabolites.
    Sharma U; Chaudhury K; Jagannathan NR; Guha SK
    Reproduction; 2001 Sep; 122(3):431-6. PubMed ID: 11597307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG.
    Chaki SP; Das HC; Misro MM
    Contraception; 2003 Jan; 67(1):73-8. PubMed ID: 12521662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical mechanism-mediated time-dependent effect on sperm of human and monkey vas implanted polyelectrolyte contraceptive.
    Guha SK
    Asian J Androl; 2007 Mar; 9(2):221-7. PubMed ID: 17334590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the micro-structural properties of RISUG--a newly developed male contraceptive.
    Kumar S; Roy S; Chaudhury K; Sen P; Guha SK
    J Biomed Mater Res B Appl Biomater; 2008 Jul; 86(1):154-61. PubMed ID: 18161821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative suitability of DMSO and NaHCO3 for reversal of RISUG® induced long-term contraception.
    Ansari AS; Hussain M; Khan SR; Lohiya NK
    Andrology; 2016 Mar; 4(2):306-13. PubMed ID: 26748683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RISUG (reversible inhibition of sperm under guidance)--an antimicrobial as male vas deferens implant for HIV free semen.
    Guha SK
    Med Hypotheses; 2005; 65(1):61-4. PubMed ID: 15893119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the membrane integrity of human sperm treated with a new injectable male contraceptive.
    Chaudhury K; Bhattacharyya AK; Guha SK
    Hum Reprod; 2004 Aug; 19(8):1826-30. PubMed ID: 15192063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of drugs for male fertility regulation: a prospectus and some preliminary data. World Health Organization Task Force on Psychosocial Research in Family Planning.
    Contraception; 1980 Feb; 21(2):121-34. PubMed ID: 6445254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RISUG: an intravasal injectable male contraceptive.
    Lohiya NK; Alam I; Hussain M; Khan SR; Ansari AS
    Indian J Med Res; 2014 Nov; 140 Suppl(Suppl 1):S63-72. PubMed ID: 25673546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Male contraception: expanding reproductive choice.
    Rajalakshmi M
    Indian J Exp Biol; 2005 Nov; 43(11):1032-41. PubMed ID: 16313066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives in non-hormonal male contraception.
    Mruk DD
    Trends Endocrinol Metab; 2008 Mar; 19(2):57-64. PubMed ID: 18291665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
    Meriggiola MC; Bremner WJ; Paulsen CA; Valdiserri A; Incorvaia L; Motta R; Pavani A; Capelli M; Flamigni C
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation through genotoxicity and apoptotic markers following RISUG
    Ansari AS; Badar A; Lohiya NK
    Reprod Toxicol; 2018 Oct; 81():84-92. PubMed ID: 30036573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): A clinical experience.
    Sharma RS; Mathur AK; Singh R; Das HC; Singh GJ; Toor DPS; Guha SK
    Indian J Med Res; 2019 Jul; 150(1):81-86. PubMed ID: 31571633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topological alterations in human spermatozoa associated with the polyelectrolytic effect of RISUG.
    Kumar S; Chaudhury K; Sen P; Guha SK
    Micron; 2006; 37(6):526-32. PubMed ID: 16504524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future perspectives in male contraception.
    Costantino A; Cerpolini S; Perrone AM; Ghi T; Pelusi C; Pelusi G; Meriggiola MC
    Minerva Ginecol; 2007 Jun; 59(3):299-310. PubMed ID: 17576406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contraceptive development for the future].
    Zatuchni GI
    Contracept Fertil Sex (Paris); 1984 Jun; 12(6):769-79. PubMed ID: 12313176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.
    Meriggiola MC; Costantino A; Cerpolini S; Bremner WJ; Huebler D; Morselli-Labate AM; Kirsch B; Bertaccini A; Pelusi C; Pelusi G
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5818-26. PubMed ID: 14671175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.